After 52 weeks, 75% on Gilead's drug had a normal liver marker, versus 16% on placebo.
Gilead's Livdelzi showed 75.4% of patients achieving normal liver marker levels after 52 weeks, vs. 16.1% on placebo, in a Phase 3 trial for PBC. Results will be presented at The Liver Meeting 2026 and published in the Journal of Hepatology. Gilead plans to engage with global regulators based on these findings.
How this was made
The 30-second read
Why it matters
Data suggest a strong efficacy signal that could drive regulatory discussions and market re‑rating of Gilead's liver‑disease franchise.
Market read
First‑time disclosure of pivotal trial results that could materially affect Gilead's valuation and the PBC therapeutic space.
What to watch
Potential regulatory delays and competition from other PBC agents could limit impact.
Background
Gilead announced Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis patients with ALP 1‑1.67× ULN.
Ticker impact
Phase 3 IDEAL trial shows 75% ALP normalization with Livdelzi versus 16% for placebo, new data disclosed today.
likely upward pressure as market prices in potential label expansion.
First disclosure of statistically significant efficacy in a previously underserved PBC patient subgroup.
Market effects
May boost broader PBC and liver‑disease therapeutic sector, encouraging peer biotech valuations.
U.S. biotech market could see modest gains on the news.
Limited to investors tracking liver‑disease drug pipelines.
Counterpoint
Skeptics may question long‑term safety and real‑world effectiveness, tempering upside.
Key entities
- companyGilead Sciences
Pharmaceutical company developing Livdelzi for PBC.
- drugLivdelzi (seladelpar)
Oral PPAR‑delta agonist evaluated in the IDEAL Phase 3 trial.
